Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: Development and immunohistochemical application in neuroendocrine tumors

Neuroendocrinology

Volumn 95, Issue 3, 2012, Pages 232-247

  Schmid, Herbert A ^a   Lambertini, Chiara ^a   Van Vugt, Harmke H ^a   Barzaghi Rinaudo, Patrizia ^a   Schäfer, Judith ^b   Hillenbrand, Rainer ^a   Sailer, Andreas W ^a   Kaufmann, Martina ^a   Nuciforo, Paolo ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Immunohistochemistry; Monoclonal antibodies; Neuroendocrine tumors; Somatostatin receptors

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SSTR3; MONOCLONAL ANTIBODY SSTR5; MONOCLONAL ANTIBODY SSTRA; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; AGGRESSION; ARTICLE; CELLULAR DISTRIBUTION; FEMALE; GASTROINTESTINAL NEUROENDOCRINE TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ARABIDOPSIS PROTEINS; CELL LINE, TRANSFORMED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR TRANSFERASES; MALE; MICE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROTEIN BINDING; RECEPTORS, SOMATOSTATIN; TRANSFECTION;

EID: 84860734631     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000330616     Document Type: Article

References (71)

1. Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994; 135: 2814-2817. (Pubitemid 24377451)
2. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J: SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133-1140. (Pubitemid 13243115)
3. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716. (Pubitemid 34552506)
4. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C: Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003; 2: 999-1017. (Pubitemid 37540581)
5. Reubi JC, Laissue J, Krenning E, Lamberts SW: Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43: 27-35.
6. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC: Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994; 733: 122-137.
7. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA 1992; 89: 251-255.
8. Guillermet-Guibert J, Lahlou H, Pyronnet S, Bousquet C, Susini C: Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: Molecular aspects. Best Pract Res Clin Gastroenterol 2005; 19: 535-551. (Pubitemid 41447717)
9. Corleto VD, Nasoni S, Panzuto F, Cassetta S, Delle Fave G: Somatostatin receptor subtypes: Basic pharmacology and tissue distribution. Dig Liver Dis 2004; 36(suppl 1):S8-S16. (Pubitemid 41115484)
10. Reubi JC, Schaer JC, Laissue JA, Waser B: Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 1996; 45: 39-41.
11. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S: Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 1995; 80: 2974-2979.
12. Reubi JC, Waser B, Schaer JC, Laissue JA: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-846. (Pubitemid 32662546)
13. De Herder WW, van Der Lely A-J, Lamberts SW: Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J 1996; 72: 403-408. (Pubitemid 26237379)
14. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461-475. (Pubitemid 34591729)
15. Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J, Mendez G, Roca E: Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis 2010; 42: 220-225.
16. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD: Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751. (Pubitemid 40692562)
17. Öberg K: Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology 2004; 80(suppl 1):57-61. (Pubitemid 39382371)
18. Öberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Välimäki M: Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II: Specific NE tumour types. Acta Oncol 2004; 43: 626-636. (Pubitemid 39563935)
19. Öberg K, Kaltsas G, Ferone D, Plockinger U: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Biotherapy. Neuroendocrinology 2009; 90: 209-213.
20. Panzuto F, Nasoni S, Baccini F, Cassetta S, Corleto VD, Delle Fave G: Unlabelled somatostatin analogues in treatment of digestive endocrine tumours. Dig Liver Dis 2004; 36(suppl 1):S42-S47. (Pubitemid 41115489)
21. Plöckinger U, Wiedenmann B: Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 145-162.
22. Plöckinger U, Wiedenmann B: Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451(suppl 1):S71-S80. (Pubitemid 47283378)
23. Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, Mayer C, Aminossadati B, Pape U-F, Bläker M, Harder J, Arnold C, Gress T, Arnold R, and the PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol 2009; 27: 4656-4663.
24. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46: 723-734. (Pubitemid 47123757)
25. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'Dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP: Overview of results of peptide receptor radionuclide therapy with three radiolabeled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):62S-66S. (Pubitemid 47619020)
26. Öberg K, Eriksson B: Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 265-276. (Pubitemid 40347816)
27. De Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van Der Lely AJ, Krenning EP: Neuroendocrine tumors and somatostatin: Imaging techniques. J Endocrinol Invest 2005; 28: 132-136.
28. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P: Octreotide in insulinoma patients: Efficacy on hypoglycemia, relationships with Octreoscan - scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005; 152: 757-767. (Pubitemid 40744545)
29. Slooter GD, Mearadji A, Breeman WA, Marquet RL, De Jong M, Krenning EP, van Eijck CH: Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 2001; 88: 31-40. (Pubitemid 32066053)
30. Reubi JC, Waser B: Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30: 781-793. (Pubitemid 36612963)
31. Körner M, Eltschinger V, Waser B, Schonbrunn A, Reubi JC: Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: Lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 2005; 29: 1642-1651.
32. Hannon JP, Petrucci C, Fehlmann D, Viollet C, Epelbaum J, Hoyer D: Somatostatin sst2 receptor knock-out mice: Localisation of sst1-5 receptor mRNA and binding in mouse brain by semi-quantitative RT-PCR, in situ hybridisation histochemistry and receptor autoradiography. Neuropharmacology 2002; 42: 396-413. (Pubitemid 34230492)
33. Albérini JL, Meunier B, Denzler B, Devillers A, Tass P, Dazord L, Le Simple T, Laissue J, De Jong R, Le Cloirec J, Reubi JC, Bourguet P: Somatostatin receptor in breast cancer and axillary nodes: Study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat 2000; 61: 21-32. (Pubitemid 30440547)
34. Li M, Li W, Kim HJ, Yao Q, Chen C, Fisher WE: Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 2004; 119: 130-137. (Pubitemid 38625638)
35. Pisarek H, Stepien T, Kubiak R, Borkowska E, Pawlikowski M: Expression of somatostatin receptor subtypes in human thyroid tumors: The immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res 2009; 2: 1.
36. Taboada GF, Luque RM, Neto LV, De O Machado E, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, De Carvalho DP, Kineman RD, Gadelha MR: Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 2008; 158: 295-303. (Pubitemid 351404992)
37. Hofland LJ, Liu Q, van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, Schonbrunn A, Lamberts SW: Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999; 84: 775-780. (Pubitemid 29075720)
38. Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, Arnold R: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002; 50: 52-60. (Pubitemid 34028303)
39. Mundschenk J, Unger N, Schulz S, Höllt V, Schulz S, Steinke R, Lehnert H: Somatostatin receptor subtypes in human pheochromocytoma: Subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003; 88: 5150-5157. (Pubitemid 37452710)
40. Papotti M, Croce S, Bellò M, Bongiovanni M, Allia E, Schindler M, Bussolati G: Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001; 439: 787-797. (Pubitemid 33141324)
41. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J: Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab 1998; 83: 3746-3749. (Pubitemid 28500920)
42. Volante M, Brizzi MP, Faggiano A, Rosa SL, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De RG, Dogliotti L, Colao A, Papotti M: Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007; 20: 1172-1182. (Pubitemid 47609066)
43. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J: Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010; 34: 300-313.
44. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S: Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 2008; 93: 1203-1210. (Pubitemid 351519711)
45. Ferone D, De Herder WW, Pivonello R, Kros JM, van Koetsveld PM, De Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ: Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 2008; 93: 1412-1417. (Pubitemid 351522738)
46. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S: Reassessment of sst 2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 2008; 93: 4519-4524. (Pubitemid 352789555)
47. Life Science Information Network. 2010. Available at: Http://www.ihcworld.com/.
48. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847. (Pubitemid 28331029)
49. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol 1990; 215: 403-410.
50. Harlow E, Lane D: Antibodies: A Laboratory Manual. New York, Cold Spring Harbor Laboratory Press, 1988.
51. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 1989; 49: 1052-1056. (Pubitemid 19064367)
52. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC: Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: A quantitative doublelabel immunohistochemical analysis. Diabetes 1999; 48: 77-85. (Pubitemid 29019355)
53. Portela-Gomes GM, Stridsberg M, Grimelius L, Öberg K, Janson ET: Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol 2000; 8: 126-132. (Pubitemid 30609973)
54. Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H: Systemic distribution of somatostatin receptor subtypes in human: An immunohistochemical study. Endocr J 2005; 52: 605-611. (Pubitemid 41609051)
55. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Saeger W, Schmid KW, Mann K, Petersenn S: Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin Endocrinol (Oxf) 2008; 68: 850-857. (Pubitemid 351703940)
56. Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K: SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 2010; 48: 142-147.
57. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET: Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol 2007; 18: 79-85. (Pubitemid 47574991)
58. Hofland LJ, Lamberts SW: The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24: 28-47. (Pubitemid 36223278)
59. Jacobs S, Schulz S: Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol 2008; 286: 58-62. (Pubitemid 351680240)
60. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S: Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009; 94: 654-661.
61. Reubi JC, Waser B, Cescato R, Gloor B, Stettler C, Christ E: Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. J Clin Endocrinol Metab 2010; 95: 2343-2350.
62. Fjällskog ML, Ludvigsen E, Stridsberg M, Öberg K, Eriksson B, Janson ET: Expression of somatostatin receptor subtypes 1-5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20: 59-67. (Pubitemid 36344027)
63. Reubi JC: Peptide receptor expression in GEP-NET. Virchows Arch 2007; 451(suppl 1):S47-S50. (Pubitemid 47283376)
64. Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 1989; 49: 7002-7009. (Pubitemid 20016583)
65. Reubi JC, Kvols L, Krenning E, Lamberts SW: Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39: 78-81. (Pubitemid 20286341)
66. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW: Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987; 47: 5758-5764. (Pubitemid 18046777)
67. Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SW: Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiationdependent relationship in glial tumors. Am J Pathol 1989; 134: 337-344. (Pubitemid 19063889)
68. De Sá SV, Corrêa-Giannella ML, Machado MC, De Souza JJ, Pereira MA, Patzina RA, Siqueira SA, Machado MC, Giannella-Neto D: Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer 2006; 13: 69-78.
69. Cordelier P, Estève J-P, Bousquet C, Delesque N, O'Carroll A-M, Schally AV, Vaysse N, Susini C, Buscail L: Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA 1997; 94: 9343-9348. (Pubitemid 27357831)
70. Sharma K, Patel YC, Srikant CB: C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 1999; 13: 82-90. (Pubitemid 29022281)
71. Corleto VD, Falconi M, Panzuto F, Milione M, De Luca O, Perri P, Cannizzaro R, Bordi C, Pederzoli P, Scarpa A, Delle Fave G: Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. Neuroendocrinology 2009; 89: 223-230.